Ultrathin bioresorbable polymer sirolimus-eluting stent technology in elective and urgent PCI – BIOFLOW V 3-year data shows superiority for target vessel MI, target lesion failure and definite late/very late stent thrombosis.
Ultrathin StrutBioresorbable-polymer stent sets new standard in drug-eluting stent technology
Printable Q&A for Offline SubmissionQuiz-summary
0 of 10 questions completed
Questions:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
Information
You have already completed the module before. Hence you can not start it again.
Module is loading…
You have to finish following quiz, to start this quiz:
Results
Results
Time has elapsed
Categories
- Not categorized 0%
-
Thank you, we will review your submission and notify you of your results via email.
If not received within 5 hours due to spam, don’t worry, it will show in your profile.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- Answered
- Review
- Question 1 of 10
1. Question
1. The BIOFLOW V clinical trial included patients with:
- Question 2 of 10
2. Question
2. Patients were eligible for the trial if:
- Question 3 of 10
3. Question
3. The thickness of the ultrathin strut used in the BIOFLOW trial for <3mm diameter struts is:
- Question 4 of 10
4. Question
4. Patients entered into the trial were graded for angiographic complexity; what percentage of patients had moderate/severe vessel tortuosity?
- Question 5 of 10
5. Question
5. The Orsiro stent elutes what percentage of the sirolimus (1.4µg/mm2) in the first 90 days?
- Question 6 of 10
6. Question
6. TLF in patients who received the BP SES was what percentage lower than in those who received the comparator DP EES?
- Question 7 of 10
7. Question
7. What percentage of patients experienced target vessel-related MI in the BP SES arm over the three-year period?
- Question 8 of 10
8. Question
8. Target lesion revascularisation caused by ischaemia was how much lower in the bioresorbable stent arm?
- Question 9 of 10
9. Question
9. Stent thrombosis, either definite/probable, was how much lower using the ultrathin bioresorbable stent than the DP EES?
- Question 10 of 10
10. Question
10. In a meta-analysis of eight RCTs (>10 000 patients), when using an ultrathin biodegradable stent TLF was on average how much lower than with a second-generation DP EES?
Do you like this? Share with a colleague
